Definitive chemoradiation for locoregional recurrences of esophageal cancer after primary curative treatment

Summary
The aim of this study was to determine the outcome of salvage definitive chemoradiation (dCRT) for a locoregional recurrence after any prior curative treatment outside previously irradiated areas. Thirty‐nine patients treated between January 2005 and December 2014 were reviewed for locoregional recurrent esophageal cancer outside previously irradiated areas. All patients received salvage treatment with external beam radiotherapy (50.4 Gy in 28 fractions) combined with weekly concurrent paclitaxel and carboplatin. The median follow‐up period was 15 months (range 1.7–120). The median overall survival (OS) for all patients after salvage dCRT was 22 months (95% CI 6.2–37.6). The 1‐, 3‐, and 5‐year OS was 72%, 31%, and 28%, respectively. Median survival after salvage dCRT for a regional lymph node recurrence was 33 months (95% CI 5.8–60.3) versus 14 months (95% CI 6.8–21.6) for a recurrence at the anastomosis (P = 0.022, logrank). Median OS was 35 months for the squamous cell carcinoma group and 19 months for the adenocarcinoma group (P = 0.67). Sixteen of 39 patients developed a locoregional recurrence after salvaged dCRT. The median locoregional recurrence‐free survival (LRFS) was 24 months. The 1‐, 3‐, and 5‐year LRFS was 79%, 36%, and 36%, respectively. Median disease‐free survival (DFS) was 15 months. The 1‐, 3‐, and 5‐year DFS was 66%, 27%, and 27%, respectively. Of 16 patients, 8 (50%) with a primary failure at the site of t...

Source: Diseases of the Esophagus - October 20, 2016 Category: Gastroenterology Authors: P. M. Jeene, E. Versteijne, M. I. van Berge Henegouwen, J. J. G. H. M. Bergmann, E. D. Geijsen, K. Muller, H. W. M. van Laarhoven, M. C. C. M Hulshof Tags: Original Article Source Type: research